A Phase 3b, Multicenter, Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

Trial status: Authorised For HS indication: ANdT count of 0-2 at each visit, For vitiligo indication: Change from baseline of the initial parent study (INCB 54707-303 or INCB 54707-304) in F-VASI score at each visit, For vitiligo indication: Change from baseline of the initial parent study (INCB 54707-303 or INCB 54707-304) in T-VASI score at each visit, For PN indication: Itch NRS score of 0 or 1 at each visit, For PN indication: IGA-CPG-S score of 0 or 1 at each visit TEAEs reported in participants receiving povorcitinib

For HS indication: ANdT count of 0-2 at each visit, For vitiligo indication: Change from baseline of the initial parent study (INCB 54707-303 or INCB 54707-304) in F-VASI score at each visit, For vitiligo indication: Change from baseline of the initial parent study (INCB 54707-303 or INCB 54707-304) in T-VASI score at each visit, For PN indication: Itch NRS score of 0 or 1 at each visit, For PN indication: IGA-CPG-S score of 0 or 1 at each visit

Age group: 65+ years, 18-64 years Gender: Female, Male Target enrollment: 845 participants